Get started
Zevra Therapeutics, Inc.Zevra Therapeutics, Inc.Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsOptionsETFs
Full chart
Full chart

Compare with Zevra Therapeutics, Inc.



Key stats


Market capitalization
‪663.91 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
12.34
Basic EPS (TTM)
0.96 USD
Net income (FY)
‪77.58 M‬ USD
Revenue (FY)
‪106.47 M‬ USD
Shares float
‪58.58 M‬
Beta (1Y)
1.22

Latest earnings


Last report date
Aug 5, 2026
Report period
Q2 2026
EPS
0.14 USD
Revenue
‪39.66 M‬ USD
Earnings call summary

Q2 2026 revenue rose 53% year-over-year to $39.7 million, led by strong MIPLYFFA U.S. sales and expanding adoption across both adult and pediatric NPC patients. Cash reserves reached $260.2 million, supporting ongoing investments and pipeline progress, while the company advances EU regulatory efforts for arimoclomol.

Employees


Employees (FY)
61
Change (1Y)
+2+3.39%
Revenue / Employee (1Y)
‪1.75 M‬ USD
Net income / Employee (1Y)
‪1.27 M‬ USD

Details


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Neil F. McFarlane
Website
zevra.com
Headquarters
Boston
Founded
2006
IPO date
Jan 8, 2021
ISIN
US4884452065
CUSIP
488445206
FIGI
BBG0026ZG1F5
Identifiers
ISIN US4884452065
CFI code
ESVUFR
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


JSMD
Janus Henderson Small/Mid Cap Growth Alpha ETF
Weight0.68%
Market value‪7.52 M‬
IBB
iShares Biotechnology ETF
Weight0.05%
Market value‪4.89 M‬
XPH
State Street SPDR S&P Pharmaceuticals ETF
Weight0.93%
Market value‪4.88 M‬
VTWO
Vanguard Russell 2000 ETF
Weight0.03%
Market value‪4.86 M‬
IWN
iShares Russell 2000 Value ETF
Weight0.03%
Market value‪4.27 M‬
PSC
Principal U.S. Small-Cap ETF
Weight0.10%
Market value‪2.38 M‬
IWC
iShares Microcap ETF
Weight0.15%
Market value‪2.31 M‬
FDLS
Inspire Fidelis Multi Factor ETF
Weight0.82%
Market value‪2.01 M‬
IWO
iShares Russell 2000 Growth Fund
Weight0.01%
Market value‪1.96 M‬
PTH
Invesco Dorsey Wright Healthcare Momentum ETF
Weight0.73%
Market value‪1.88 M‬
DWAS
Invesco Dorsey Wright SmallCap Momentum ETF
Weight0.33%
Market value‪1.53 M‬

Explore more ETFs 

Frequently asked questions


The current price of ZVRA is 11.32 USD — it has decreased by −2.27% in the past 24 hours. Watch Zevra Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Zevra Therapeutics, Inc. stocks are traded under the ticker ZVRA.
ZVRA stock has fallen by −1.11% compared to the previous week, the month change is a −14.79% fall, over the last year Zevra Therapeutics, Inc. has showed a 20.43% increase.
We've gathered analysts' opinions on Zevra Therapeutics, Inc. future price: according to them, ZVRA price has a max estimate of 35.00 USD and a min estimate of 20.00 USD. Watch ZVRA chart and read a more detailed Zevra Therapeutics, Inc. stock forecast: see what analysts think of Zevra Therapeutics, Inc. and suggest that you do with its stocks.
ZVRA reached its all-time high on Aug 14, 2015 with the price of 418.40 USD, and its all-time low was 1.94 USD and was reached on May 21, 2020. View more price dynamics on ZVRA chart.
See other stocks reaching their highest and lowest prices.
ZVRA stock is 5.09% volatile and has beta coefficient of 1.22. Track Zevra Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Zevra Therapeutics, Inc. there?
Today Zevra Therapeutics, Inc. has the market capitalization of ‪663.91 M‬, it has decreased by −19.85% over the last week.
Yes, you can track Zevra Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Zevra Therapeutics, Inc. is going to release the next earnings report on Nov 11, 2026. Keep track of upcoming events with our Earnings Calendar.
ZVRA earnings for the last quarter are 0.14 USD per share, whereas the estimation was 0.11 USD resulting in a 27.27% surprise. The estimated earnings for the next quarter are 0.16 USD per share. See more details about Zevra Therapeutics, Inc. earnings.
Zevra Therapeutics, Inc. revenue for the last quarter amounts to ‪39.66 M‬ USD, despite the estimated figure of ‪33.88 M‬ USD. In the next quarter, revenue is expected to reach ‪37.08 M‬ USD.
ZVRA net income for the last quarter is ‪8.39 M‬ USD, while the quarter before that showed ‪36.32 M‬ USD of net income which accounts for 0.00% change. Track more Zevra Therapeutics, Inc. financial stats to get the full picture.
No, ZVRA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 14, 2026, the company has 61 employees. See our rating of the largest employees — is Zevra Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Zevra Therapeutics, Inc. EBITDA is ‪40.51 M‬ USD, and current EBITDA margin is −0.17%. See more stats in Zevra Therapeutics, Inc. financial statements.
Like other stocks, ZVRA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Zevra Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Zevra Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Zevra Therapeutics, Inc. stock shows the buy signal. See more of Zevra Therapeutics, Inc. technicals for a more comprehensive analysis.